Valued at a market cap of $27.5 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
DXCM is expected to release its Q2 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $0.61 on a diluted basis, up 27.1% from $0.48 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.